Conduit Pharmaceuticals receives U.S. patent approval for AZD1656

Conduit Pharmaceuticals (CDT) announces that the United States Patent and Trademark Office, USPTO, has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases, including Lupus and ANCA Vasculitis. With this critical composition of matter patent protection now secured, the Company is strategically positioned to advance AZD1656 into clinical development, with clinical trial plans now in final stages of preparation. “Securing USPTO approval for AZD1656’s composition of matter patent is a major milestone, further solidifying our intellectual property portfolio and strategic value,” said Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals. “With the composition of matter patent now in place in this critical market, this also indicates an increased likelihood of patent success in the outstanding additional geographies worldwide.”